Orforglipron vs. semaglutide: is oral GLP-1 actually ready?

What did @drkazarian actually say?

The creator is excited about orforglipron, a new oral GLP-1 receptor agonist from Eli Lilly. They claim it produced "11% body weight loss" over 72 weeks in trials, call it "not a peptide," say it has a "similar safety profile" to existing GLP-1 drugs, and argue the real value is market competition driving prices down. They also flag Lilly's pipeline including retatrutide arriving "next summer" and question what Novo Nordisk does in response.

The pronunciation jokes aside, this is a fairly substantive take on competitive GLP-1 market dynamics from someone who appears to work in a weight management clinic. Let's see how it holds up.

Does the science back this up?

The 11% weight loss figure is in the right ballpark but deserves more precision. The phase 2 trial data published by Dahl et al. (2023, NEJM) showed orforglipron at the highest dose achieved roughly 14.7% weight reduction at 36 weeks in people with obesity without diabetes. A separate phase 2 trial in type 2 diabetes showed around 9% reduction. The 72-week figure the creator cites likely refers to a different data cut or the ongoing phase 3 ATTAIN program. Saying "11%" without specifying dose, population, or trial phase is the kind of shorthand that sounds clean but flattens real variation in outcomes.

The "not a peptide" claim is accurate and actually important. Orforglipron is a small-molecule, non-peptide GLP-1 receptor agonist. That distinction matters because it can be taken orally without the absorption limitations of semaglutide tablets, and it does not require refrigeration. This is genuinely different from oral semaglutide (Rybelsus), which is still a peptide requiring specific dosing conditions.

What did they get wrong (or right)?

The safety profile claim is mostly accurate but soft. Orforglipron's phase 2 data showed GI side effects consistent with the GLP-1 class, primarily nausea, diarrhea, and vomiting. That tracks. But "similar safety profile" is doing a lot of work here. Long-term safety data simply does not exist yet for orforglipron at scale. Phase 3 trials are still ongoing as of mid-2025. Calling it similar to established agents is reasonable as a hypothesis, not as a settled conclusion.

The pricing commentary is where the creator is genuinely right and worth hearing. The "$150 a month" bait-and-switch on GLP-1 pricing is a real and documented problem in direct-to-consumer telehealth marketing. Introductory pricing that jumps to $300 or more is a known pattern. The argument that more approved products increase competitive pressure and lower costs is standard health economics, and it's correct in theory, though in practice, branded GLP-1s have not followed typical price competition curves in the U.S.

The retatrutide "next summer" claim is unverifiable without a specific trial read-out date, and Lilly has not publicly committed to that timeline for approval.

What should you actually know?

Orforglipron is real, it is in phase 3 trials, and it is a genuinely different formulation class from existing GLP-1 drugs. If it clears FDA review, a once-daily oral small-molecule GLP-1 agonist without peptide limitations could expand access meaningfully, particularly for people who have needle aversion or storage constraints. That is not hype, that is a legitimate clinical advantage being tested right now.

But no approval date exists yet. The creator's enthusiasm is understandable, but patients watching this should know that orforglipron is not available, the 11% figure comes from dose-specific phase 2 data, and the full safety picture including cardiovascular outcomes will come from the ATTAIN-CVOT trial, which has not reported. Retatrutide, a triple agonist targeting GLP-1, GIP, and glucagon receptors, showed up to 24% weight loss in phase 2 (Jastreboff et al., 2023, NEJM), but it also has no approval timeline confirmed for the U.S.

• Orforglipron is a non-peptide oral GLP-1 agonist, still in phase 3 trials as of 2025.
• Phase 2 weight loss results ranged from 9% to nearly 15% depending on dose and population.
• Cardiovascular outcome data is not yet available.
• Retatrutide is earlier in its regulatory path than the creator implies.
• Competitive pricing pressure from multiple GLP-1 approvals is economically plausible but not guaranteed in the U.S. market.